Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was ended for strategic reasons and changes in the external environment. The safety profile and risk benefit ratio for PF-0674775 remained unchanged.

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: PF-06747775
DRUG: Palbociclib
DRUG: Avelumab

Sponsor

Pfizer